Haematological malignancies
Cellcentric Limited focuses on cancers of the blood, bone marrow, lymph, and lymphatic system, with activity spanning acute myeloid leukaemia and higher-risk myelodysplastic syndrome.
- Acute Myeloid Leukaemia
- Higher-risk Myelodysplastic Syndrome
- Blood and bone marrow cancers
The sponsor’s research interest extends to aggressive myeloid disorders requiring targeted approaches in malignant haematology.
Plasma cell and lymphoid cancers
The company also studies multiple myeloma and non-Hodgkin lymphoma, reflecting interest in both plasma cell disease and diverse lymphoid malignancies.
- Multiple Myeloma
- Non-Hodgkin Lymphoma
- Lymphatic system cancers
These areas place emphasis on cancers with distinct biological features across the immune and haematologic systems.
Oncology drug development
Cellcentric Limited’s clinical research includes investigation of an experimental oncology agent in solidly defined haematology settings and related cancer therapeutics.
- Experimental anti-cancer therapy
- Monotherapy evaluation
- Combination cancer treatment
The therapeutic interest is centered on treatment options for patients with advanced blood and marrow cancers.
Translational haematology research
The sponsor’s trial activity is directed toward conditions at the interface of haematology and oncology, with a focus on diseases that involve malignant transformation within the marrow microenvironment.
- Marrow-based malignancies
- Leukaemia research
- Lymphoma research
This includes clinical interest in therapeutic strategies for cancers arising from myeloid and lymphoid lineages.
